A lit­tle-known biotech run­ning low on cash looks to get its own $100M IPO from pan­dem­ic mar­ket

It’s been heady for biotechs break­ing in­to a pan­dem­ic stock mar­ket: $233 mil­lion for ADC Ther­a­peu­tics, $165 mil­lion for Zen­tal­is, and $120 mil­lion for ORIC. Now a com­pa­ny that emerged from stealth just 8 months ago — and is now run­ning low on cash — is try­ing to get in on the 9-fig­ure game.

South San Fran­cis­co-based Ap­plied Mol­e­c­u­lar Trans­port has filed for a $100 mil­lion IPO. Found­ed and led by long­time life sci­ences con­sul­tant Tahir Mah­mood, the com­pa­ny builds oral drugs around a car­ri­er mol­e­cule that can cross pro­tec­tive lin­ings in­to the im­mune-cell heavy ar­eas of the gut. They de­buted in Sep­tem­ber, af­ter they be­gan dos­ing Phase I for their lead pro­gram, an ul­cer­a­tive col­i­tis drug that re­cent­ly com­plet­ed ear­ly test­ing in East­ern Eu­rope.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA